A sizable proportion of opioid-naïve patients who undergo stone surgery become chronic opioid users, according to a study conducted by urologists from Emory University, Atlanta.
Cheryl Guttman Krader
Patients who receive a radiation oncology consultation after being diagnosed with localized prostate cancer are much more likely to receive active therapy than men managed only by a urologist, and the men seen by a radiation oncologist are particularly likely to be treated with radiation therapy, according to a Canadian population-based, retrospective cohort study.
A recent study found that sacral neuromodulation monotherapy was efficacious as a third-line treatment.
“The results with neoadjuvant atezolizumab are preliminary but promising in this area of high unmet need,” says researcher Thomas Powles, MD.
“We believe that referral for kidney SABR is worthy of consideration in patients with solitary-kidney RCC who are faced with limited and risky management options,” says researcher Rohann Correa, MD, PhD.
Body mass index appears to be a prognostic factor for treatment outcomes in patients with metastatic renal cell carcinoma, but the direction of the association might vary across treatment modalities.
Results of a prospective, multicenter study validate the clinical performance of a PSA isoform assay (IsoPSA) for predicting high-grade prostate cancer, Eric A. Klein, MD, reported at the AUA annual meeting in San Francisco.
Results of the prospective MedLift study establish the efficacy and safety of the Prostatic Urethral Lift (PUL [UroLift System]) procedure for treatment of symptomatic BPH in men with an enlarged median lobe.
A multi-institutional consortium study conducted to fill a gap in knowledge about long-term outcomes of stereotactic body radiation therapy (SBRT) for low- and intermediate-risk prostate cancer shows that both the long-term efficacy and safety of SBRT compare favorably with the profiles of other established radiotherapy modalities.
A study of men diagnosed with prostate cancer in the setting of a community urology practice showed that adherence with active surveillance is good after 3 years of follow-up.